ADA糖尿病诊疗标准执行纲要中英文对照

上传人:ni****g 文档编号:431726554 上传时间:2023-11-29 格式:DOCX 页数:36 大小:84KB
返回 下载 相关 举报
ADA糖尿病诊疗标准执行纲要中英文对照_第1页
第1页 / 共36页
ADA糖尿病诊疗标准执行纲要中英文对照_第2页
第2页 / 共36页
ADA糖尿病诊疗标准执行纲要中英文对照_第3页
第3页 / 共36页
ADA糖尿病诊疗标准执行纲要中英文对照_第4页
第4页 / 共36页
ADA糖尿病诊疗标准执行纲要中英文对照_第5页
第5页 / 共36页
点击查看更多>>
资源描述

《ADA糖尿病诊疗标准执行纲要中英文对照》由会员分享,可在线阅读,更多相关《ADA糖尿病诊疗标准执行纲要中英文对照(36页珍藏版)》请在金锄头文库上搜索。

1、最新 精品 Word 欢迎下载 可修改2022年ADA糖尿病诊疗标准执行纲要美国糖尿病协会王新军 于文 译滨州医学院附属滨州市人民医院内分泌科,滨州,256610目前糖尿病的诊断标准l A1C6.5%。试验应该用美国糖化血红蛋白标准化计划组织(National Glycohemoglobin Standardization Program,NGSP)认证的方法进行。并与(Diabetes Control and Complications Trial,DCCT)的检测进行标化l 空腹血糖(FPG)7.0 mmol/L。空腹的定义是至少8小时未摄入热量,或l OGTT 2h血糖11.1 mmol

2、/L。试验应按照世界卫生组织(WHO)的标准进行,用75 g无水葡萄糖溶于水作为糖负荷l 有高血糖的典型症状或高血糖危象,随机血糖11.1 mmol/Ll 如无明确的高血糖症状,结果应重复检测确认。Current criteria for the diagnosis ofdiabetes A1C6.5%. The test should be per-formed in a laboratory using a methodthatisNationalGlycohemoglobinStan-dardization Program (NGSP)-certifiedand standardized

3、 to the Diabetes Con-trol and Complications Trial (DCCT)assay fasting plasma glucose (FPG)126mg/dl (7.0 mmol/l). Fasting is definedas no caloric intake for at least 8 h, or 2-h plasma glucose200 mg/dl (11.1mmol/l) during an oral glucose toler-ance test (OGTT). The test should beperformed as describe

4、d by the WorldHealth Organization, using a glucoseload containing the equivalent of 75 ganhydrous glucose dissolved in water in a patient with classic symptoms ofhyperglycemiaorhyperglycemiccrisis,a random plasma glucose200 mg/dl(11.1 mmol/l) intheabsenceofunequivocalhypergly-cemia, result should be

5、 confirmed byrepeat testing.new在无症状患者中进行糖尿病筛查 在无症状的成人,如超重或肥胖(BMI25kg/m2)并有一个以上其他糖尿病危险因素(见“2022年糖尿病诊疗标准”中的表4),应该从任何年龄开始筛查糖尿病并评估将来糖尿病的风险。对没有这些危险因素的人群,应从45岁开始筛查。(B) 如果检查结果正常,至少每3年复查一次。(E) 为筛查糖尿病或评估未来糖尿病的风险,A1C、FPG或2h 75g OGTT均是适用的。(B) 对于那些已经确定未来糖尿病风险增加的人群,应该进一步评估并治疗其他心血管疾病(CVD)危险因素。(B)Testing for diabe

6、tes in asymptomaticpatients Testing to detect type 2 diabetes andassess risk for future diabetes in asymptomaticpeople should be considered inadults of any age who are overweight orobese (BMI _25 kg/m2) and who haveone or more additional risk factors fordiabetes (see Table 4 of the “Standardsof Medi

7、cal Care in Diabetes2022”).In those without these risk factors, testingshould begin at age 45 years. (B) If tests are normal, repeat testing carriedout at least at 3-year intervals isreasonable. (E) To test for diabetes or to assess risk offuture diabetes, A1C, FPG, or 2-h 75-gOGTT are appropriate.

8、(B) In those identified with increased riskfor future diabetes, identify and, if appropriateappropriate,treat other cardiovasculardisease (CVD) risk factors. (B)妊娠期糖尿病的筛查和诊断 在有危险因素的个体中,产前首次就诊时用标准的诊断标准筛查未诊断的2型糖尿病。(B) 在未知是否具有糖尿病的怀孕妇女中,在妊娠2428周用75g 2h OGTT筛查妊娠糖尿病,诊断切点见“2022年糖尿病诊疗标准”表6。(B)Detection and

9、diagnosis ofgestational diabetes mellitus (GDM) Screen for undiagnosed type 2 diabetesat the first prenatal visit in those withrisk factors, using standard diagnosticcriteria. (B) In pregnant women not known to havediabetes, screen for GDM at 2428weeks of gestation, using a 75-g 2-hOGTT and the diag

10、nostic cut points inTable 6 of the “Standards of MedicalCare in Diabetes2022”. (B) 妊娠糖尿病的妇女在产后612周筛查永久性糖尿病。(E) 有妊娠糖尿病病史的妇女应至少每3年筛查是否发展为糖尿病或糖尿病前期。(E) Screen women with GDM for persistentdiabetes 612 weeks postpartum. (E) Women with a history of GDM shouldHave life long screening for the develop-Ment

11、of diabetes or prediabetes at leastevery 3 years. (E)预防/延缓2型糖尿病 对于糖耐量异常(IGT)(A)、空腹血糖受损(IFG)(E)或A1C 在5.76.4%之间(E)的患者,应该制定长期计划,以减轻体重7%,增加体力活动,每周进行至少150分钟中等强度(如步行)的体力活动。(B) 定期随访咨询对成功非常重要。(B)Prevention/delay of type 2 diabetes Patients with impaired glucose toler-ance (IGT) (A), impaired fasting glu-cos

12、e(IFG)(E),oranA1Cof5.76.4%(E) should be referred to an effectiveongoing support program targetingweight loss of 7% of body weight andincreasing physical activity to at least150 min/week of moderate activitysuch as walking. Follow-up counseling appears to be im-portant for success. (B) 基于节约糖尿病预防的潜在医疗

13、费用,这种咨询的费用应由第三方支付。(E) 对于那些可能发展为糖尿病的高危人群,如具有多种危险因素,尤其是尽管进行了生活方式的干预后血糖仍进展(如A1C6%),可以考虑使用二甲双胍治疗以预防2型糖尿病。(B) 糖尿病前期患者应该每年进行检测以观察是否进展为糖尿病。(E) Based on potential cost-savings of dia-betes prevention, such programsshould be covered by third-party pay-ors. (E) Metformin therapy for prevention oftype 2 diabet

14、es may be considered inthose at highest risk for developing di-abetes,such as those with multiple riskfactors, especially if they demonstrateprogression of (B) Monitoring for the development of di-Abetes in those with prediabetes shouldbe performed every year. (E)血糖监测 每日多次胰岛素注射或采用胰岛素泵治疗的患者,应该进行自我检测血

15、糖(SMBG)每天3次或以上。(A) 对于胰岛素注射次数少或仅采用口服药物或医学营养治疗(MNT)的患者,SMBG或许有助于治疗成功。(E) 餐后SMBG或许有助于餐后血糖控制达标。(E) SMBG医嘱后,应确保患者获得SMBG的初始指导和定期随访评估,并用SMBG数据指导和调整治疗。(E) 对于年龄25岁以上的1型糖尿病患者进行动态血糖监测(CGM)并联合胰岛素强化治疗,是降低A1C水平的有效方法。(A) 虽然在儿童、青少年和青年患者中降低A1C的证据不强,但是CGM或许有助于该人群的治疗。这种仪器的应用与成功的治疗具有相关性。(C) CGM可以作为SMBG的一种补充,特别适宜无症状低血糖和或频发低血糖的患者。(EGlucose monitoring Self-monitoring of blood glucose(SMBG) should be carried out three ormoretimesdailyforpatientsusingmul-tipleinsulin

展开阅读全文
相关资源
正为您匹配相似的精品文档
相关搜索

最新文档


当前位置:首页 > 办公文档 > 解决方案

电脑版 |金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号